Shots:

• The expanded indication approval is based on the results of P-III FOURIER study assessing Repatha (140mg q2w- 420 mg/month) vs PBO + statin therapy in patients with cardiovascular events
• The study resulted in a reduction in risk of heart attack by 27%- risk of stroke by 21%- the risk of coronary revascularization by 22% and an overall reduction in cardiovascular events with safe and efficate results
• Repatha (evolocumab) is a mAb that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and received NMPA approval on 31 Jul- 2018 for homozygous familial hypercholesterolemia (HoFH) in adults